Primary information |
---|
sequence ID | Seq_528 |
Peptide sequence | ALHNHYTQKSLSLSPG |
CancerPDF_ID | CancerPDF_ID9796, CancerPDF_ID10296, |
PMID | 21533267,21805675 |
Protein Name | Ig gamma-2 chain C region,Ig gamma-1 chain C region |
UniprotKB Entry Name | IGHG2_HUMAN,IGHG1_HUMAN |
Fluid | Serum,Urine |
M/Z | 584.97,1752.8875 |
Charge | 3,NA |
Mass (in Da) | NA,NA |
fdr | NA,NA |
Profiling Technique | LC-MS,MALDI-TOF |
Peptide Identification technique | LC/MS/MS,MALDI-TOF-MS |
Quantification Technique | Multiple Reaction Monitoring,NA |
Labelled/Label Free | Label Free,Label Free |
FDR | 1.49,1 |
CancerPDF_ID | CancerPDF_ID9796, CancerPDF_ID10296, |
p-Value | NA,NA |
Software | MASCOT,NA |
Length | 16,16 |
Cancer Type | Lung adenocarcinoma,Muscle-invasive bladder cancer |
Database | Swissprot Database (57.4),SwissProt Database |
Modification | NA,NA |
Number of Patients | 62 lung adenocarcinoma and 30 healthy control,751 bladder cancer and 127 control |
Regulation | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal",Differentially expressed between cancer vs normal samples |
Validation | MRM-based validation of 19 candidates,Mann-Whitney tests and areas under receiver-operator characteristic |
Sensitivity | NA,NA |
Specificity | NA,NA |
Accuracy | NA,NA |
Peptide Atlas | NA |
IEDB | |